Overview and Scope
Progressive multifocal leukoencephalopathy is a severe and rare viral brain infection that primarily affects individuals with weakened immune systems. Its treatment is used to manage symptoms, slow down the progression of the disease, and prevent complications. There is no known treatment for PML and the virus’s harm cannot be reversed.
Sizing and Forecast
The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.
The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing digital health and telemedicine, growing adoption of targeted therapy, improved diagnostic tools, growing awareness of progressive multifocal leukoencephalopathy (pml). Major trends in the forecast period include technological advancements in progressive multifocal leukoencephalopathy (pml) treatment, research and clinical trials, early diagnosis and screening, development of new drug therapies.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The progressive multifocal leukoencephalopathy treatment market covered in this report is segmented –
1) By Treatment: Anti-retroviral Therapy; Antiviral Or Anti-John Cunningham Virus (JCV); Other Symptomatic
2) By Indication: HIV Or AIDS; Organ Transplantation; Multiple Sclerosis; Hematologic Malignancies
3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2023. The regions covered in the progressive multifocal leukoencephalopathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12864&type=smp
Major Driver Impacting Market Growth
The growing prevalence of human immunodeficiency virus (HIV) infection is expected to propel the growth of the progressive multifocal leukoencephalopathy market going forward. HIV is a retrovirus that attacks the immune system, specifically targeting CD4 cells (also known as T cells), which play a crucial role in helping the body fight infections. Most patients with HIV infection develop PML due to a poor immunological condition indicated by a low CD4 cell count (200/L), the single most significant cause of PML cases worldwide. When a severe HIV-related immune deficit arises, the latent JCV archetype strain in the brain may increase, leading to brain white matter lesions and PML. For instance, in December 2022, according to the Joint United Nations Programme on HIV and AIDS (UNAIDS), a Switzerland-based joint venture of the United Nations for AIDS, 630,000 (480,000–880,000) people died from AIDS-related illnesses and there were 39.0 million [33.1 million–45.7 million] people living with HIV globally. In 2022, 1.3 million [1 million–1.7 million] additional people developed HIV for the first time. Therefore, the growing prevalence of human immunodeficiency virus (HIV) infection is driving the growth of the progressive multifocal leukoencephalopathy market.
Key Industry Players
Major players in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Acorda Therapeutics, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Ipsen Pharma, Apotex Inc., Alkermes PLC, Alnylam Pharmaceuticals Inc., Genentech Inc., Karyopharm Therapeutics Inc., ARIAD Pharmaceuticals Inc., Spectrum Pharmaceuticals, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc.
The progressive multifocal leukoencephalopathy treatment market report table of contents includes:
1. Executive Summary
2. Progressive Multifocal Leukoencephalopathy Treatment Market Characteristics
3. Progressive Multifocal Leukoencephalopathy Treatment Market Trends And Strategies
4. Progressive Multifocal Leukoencephalopathy Treatment Market – Macro Economic Scenario
5. Global Progressive Multifocal Leukoencephalopathy Treatment Market Size and Growth
.
.
.
26. South America Progressive Multifocal Leukoencephalopathy Treatment Market
27. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market
28. Middle East Progressive Multifocal Leukoencephalopathy Treatment Market
29. Africa Progressive Multifocal Leukoencephalopathy Treatment Market
30. Progressive Multifocal Leukoencephalopathy Treatment Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Johnson & Johnson
- Roche Holding AG
- Merck & Co. Inc
- AbbVie Inc
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
